ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Hyperoside flavonoids protect against malathion-induced mitochondrial toxicity in the differentiated SH-SY5Y cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MitoQ alleviates malathion‑induced hepatorenal toxicity via oxidative stress and inflammation modulation.Molecular medicine reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Malathion (MAL), an organophosphorus pesticide, is known to induce mitochondrial toxicity in neuronal cells, contributing to neurodegenerative processes. This study aims to investigate the protective effects of hyperoside (HYP), a flavonoid, against mitochondrial dysfunction induced by MAL in differentiated SH-SY5Y cells. Differentiated human neuroblastoma cell lines were treated with various concentrations of MAL (0.01 to 100 mM) and HYP (10 to 40 µM). Cell viability was assessed using MTT and BrdU assays, while mitochondrial function was evaluated through ATP production, mitochondrial membrane potential (MMP), oxygen consumption rates (OCR), mitophagy-related proteins (PARKIN and PINK1) evaluation, and expression of key mitochondrial genes (i.e., ND1/5, Cy.b, CO1, and ATP 6/8). Bioinformatics analyses were also employed to identify the pathways impacted by MAL exposure, which revealed disruptions in immune responses, apoptosis regulation, and mitochondrial function. MAL treatment resulted in significant concentration-dependent cytotoxicity and reduction in cell viability (p < 0.001). HYP treatment notably increased cell viability to 115.8 ± 3.5% and 130.1 ± 3.1% of the control cells' viability at 20 and 40 µM concentrations, respectively. The cotreatment with HYP effectively restored mitochondrial function by increasing ATP levels and mitochondrial membrane potential (MMP), while also enhancing oxidative capacity (OCR). Importantly, HYP mitigated MAL-induced oxidative stress and apoptosis, restoring levels of PARKIN and PINK1 proteins, which are crucial for mitophagy. Additionally, HYP significantly enhanced the expression of mitochondrial genes involved in the electron transport chain in MAL-treated cells. These findings indicate that HYP provides significant protective effects against MAL-induced mitochondrial toxicity in differentiated SH-SY5Y cells, suggesting its potential as a therapeutic agent for mitigating pesticide-related neurotoxicity. Further research on HYP may enhance our understanding of its protective mechanisms and therapeutic applications in neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.